Floatz logo

Imgn151

Platinum-Sensitive Ovarian Cancer

AbbViePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

524 Active assets in the Platinum-Sensitive Ovarian Cancer cohort.

Asset / SponsorPhaseRating
TIL
Inge Marie Svane
Phase 2BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Olaparib
Shandong University
Phase 4BB
OTL-38
On Target Laboratories, LLC
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Kalinski, Pawel, MD, PhD
Phase 3BB

View all 50 →

Same molecule, other indications

Imgn151 is also rated in:

female reproductive organ cancerDormant
CCC
Indicative ·
53 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
48 / 100
View asset →
primary peritoneal carcinomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →